drugset / Trial / NCT02223351

Drug-Drug Interaction Study: ASP2151 and Ritonavir

NCT02223351

Phase 1 Completed 48 enrolled Maruho Europe Limited
RandomizedCrossoverOpen-labelOther

Summary

ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system. As HIV patients will be taking drugs to treat the virus this study aims to see if ASP2151 would interact with one of the drugs that is commonly prescribed to HIV patients (ritonavir).

Timeline

Start
2014-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amenamevir Small molecule 400 mg
Subject Amenamevir Small molecule 1200 mg
Subject Ritonavir Other / unclassified 600 mg Oral

Indications

No indication recorded.